For the discovery, preclinical and clinical development of bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma.
Paul G. Richardson, MD received his medical degree from the Medical College of St. Bartholomew’s Hospital in London, with postdoctoral training at St. Bartholomew’s Hospital, Newcastle University School of Medicine, the Royal Marsden Hospital, and the Beth Israel Hospital in Boston. Richardson completed fellowship in hematology/oncology at Tufts University School of Medicine, Baystate Medical Center, Harvard Medical School,and Dana-Farber Cancer Institute (DFCI), before coming on staff at DFCI in 1994. Richardson serves on the Editorial Board of the Journal of Clinical Oncology, Clinical Cancer Research, and the British Journal of Hematology. He was the founding Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core and now chairs the Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). His honors include several Partners in Excellence Awards, The Brigham and Women’s Hospital Teaching Scholars Award, The Tisch Outstanding Achievement Award for Clinical Research, and the DFCI’s George Canellos Award for Excellence in Clinical Research and Patient Care. For his contributions in myeloma, he was awarded an honorary Fellowship of the Royal College of Physicians (UK) in 2009.
Richardson has published more than 230 original articles and over 160 reviews, chapters, and editorials in various journals, including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, and Leukemia. His primary research interest is in novel therapies for myeloma, and he has been at the forefront of the clinical development of bortezomib, lenalidomide, and most recently pomalidomide. At present, he is leading multiple efforts studying the use of new agents and pioneered the development of lenalidomide, bortezomib, and dexamethasone (so called RVD), which is now widely used in the upfront treatment of multiple myeloma. He currently serves as a principal investigator for several international clinical trials evaluating the use of novel combination therapies with the goal of targeting resistance, reducing toxicity, and improving patient outcome.